Stocktoria
Xenon Pharmaceuticals Inc. XENE
Xenon Pharmaceuticals Inc. (XENE) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $7.5M at a -4612.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-05-27 | JP Morgan | Overweight (main) |
| 2026-05-12 | JP Morgan | Overweight (main) |
| 2026-05-08 | RBC Capital | Outperform (main) |
| 2026-05-08 | Needham | Buy (main) |
| 2026-03-16 | Wedbush | Outperform (main) |
| 2026-03-10 | Wells Fargo | Overweight (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.819 |
| Retained earnings / assets | -1.967 |
| EBIT / assets | -0.589 |
| Equity / liabilities | 11.318 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| XENE | Xenon Pharmaceuticals Inc. | 2/9 | 6.89 | — | — |
| ADAG | Adagene Inc. | 4/9 | -9.75 | — | — |
| CRNX | Crinetics Pharmaceuticals, Inc. | 2/9 | 6.19 | — | — |
| OVID | Ovid Therapeutics Inc. | 1/9 | 0.8 | — | -96.8% |
| ACRS | Aclaris Therapeutics, Inc. | 2/9 | -18.21 | — | -58.2% |
| WHWK | Whitehawk Therapeutics, Inc. | 2/9 | 2.98 | — | -72.5% |
| COYA | Coya Therapeutics, Inc. | 2/9 | 5.24 | — | — |
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
FAQ
Is XENE financially healthy?
Xenon Pharmaceuticals Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does XENE pay a dividend?
No, Xenon Pharmaceuticals Inc. does not currently pay a dividend.
How profitable is XENE?
In FY2025, Xenon Pharmaceuticals Inc. had a net margin of -4612.1% and a return on equity of -59.5%.
What is the analyst price target for XENE?
The average Wall-Street price target for Xenon Pharmaceuticals Inc. is $80.56, about 23.4% above the recent price, from 19 analysts.
Is XENE a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Xenon Pharmaceuticals Inc.: a Piotroski F-score of 2/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.